How many insider trades does FilingIQ track for GRCE?

FilingIQ tracks 5 Form 4 insider transactions for GRCE (Grace Therapeutics, Inc.), covering filings from Jan 8, 2026 onwards. 1 of those were filed in the last 90 days.

Are GRCE insiders net buyers or net sellers?

Across the full Form 4 history for GRCE, 1 transactions (20%) were open-market purchases and 0 (0%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does GRCE insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is GRCE in?

Grace Therapeutics, Inc. (GRCE) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $70.86M.

GRCE insider trading

NasdaqCM Healthcare

Grace Therapeutics, Inc. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

Last 90 days

Buys / sells

20% / 0%

Market cap

$70.86M

About Grace Therapeutics, Inc.

Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray of betamethasone to improve neurological symptoms of Ataxia-Telangiectasia (A-T) and GTX-101, a topical bioadhesive film-forming polymer for the treatment of pain associated with postherpetic neuralgia (PHN). The company was formerly known as Acasti Pharma Inc. and changed its name to Grace Therapeutics, Inc. in October 2024. Grace Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.

Company website: www.gracetx.com

GRCE insider activity at a glance

FilingIQ has scored 5 insider transactions for GRCE since Jan 8, 2026. The most recent filing in our index is dated Aug 14, 2026.

Across the full history, 1 open-market purchases and 0 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on GRCE insider trades is 52.0/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live GRCE trades on FilingIQ Raw filings on SEC EDGAR

Other Healthcare tickers with recent insider activity

UTHR 983

UNITED THERAPEUTICS Corp

NUVL 195

Nuvalent, Inc.

KYMR 193

Kymera Therapeutics, Inc.

GH 192

Guardant Health, Inc.

Hims & Hers Health, Inc.

Frequently asked

How many insider trades does FilingIQ track for GRCE?: FilingIQ tracks 5 Form 4 insider transactions for GRCE (Grace Therapeutics, Inc.), covering filings from Jan 8, 2026 onwards. 1 of those were filed in the last 90 days.
Are GRCE insiders net buyers or net sellers?: Across the full Form 4 history for GRCE, 1 transactions (20%) were open-market purchases and 0 (0%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does GRCE insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is GRCE in?: Grace Therapeutics, Inc. (GRCE) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $70.86M.

Methodology & sources

Every GRCE insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.